- Home
- NGNE
NGNE
Neurogene Inc.
as 06-06-2025 2:39pm EST
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 251.9M | IPO Year: | N/A |
| Target Price: | $39.83 | AVG Volume (30 days): | 213.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.88 - $74.49 | Next Earning Date: | 05-09-2025 |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neurogene Inc. (NGNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cobb Stuart | NGNE | Chief Scientific Officer | May 14 '25 | Sell | $15.15 | 6,797 | $103,003.10 | 20,794 | |
| Cvijic Christine Mikail | NGNE | President and CFO | Mar 13 '25 | Sell | $16.94 | 4,501 | $76,246.94 | 72,343 |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
Short Report: Bears bite into Krispy Kreme after another weak earnings report
Business Wire
21 days ago
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
Business Wire
a month ago
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Business Wire
a month ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Business Wire
2 months ago
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
TipRanks
2 months ago
Biotech stocks slide as Marks resignation seen being negative for sector
Business Wire
2 months ago
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.